The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Ion Channels and Channelopathies
Volume 16 - 2025 |
doi: 10.3389/fphar.2025.1545050
Administration of the KCa channel activator SKA-31 improves endothelial function in the aorta of atherosclerosis-prone mice
Provisionally accepted- 1 Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada
- 2 Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada
- 3 University of California, Davis, Davis, California, United States
Introduction: Atherosclerosis remains a major risk factor for vascular dysfunction and cardiovascular (CV) disease. Pharmacological enhancement of endothelial Ca 2+ -activated K + channel activity (i.e., KCa2.3 and KCa3.1) opposes vascular dysfunction associated with ageing and type 2 diabetes (T2D) in ex vivo and in vivo preparations. In the current study, we have investigated the efficacy of this strategy to mitigate endothelial dysfunction in the setting of atherogenesis.Male apolipoprotein E knockout (Apoe -/-) mice fed a high fat diet (HFD) were treated daily with the KCa channel activator SKA-31 (10 mg/kg), the KCa3.1 channel blocker senicapoc (40 mg/kg), or drug vehicle for 12-weeks. Endothelium-dependent and -independent relaxation and vasocontractility were measured in abdominal aorta by wire myography. The development of atherosclerosis in the thoracic aorta was characterized by Oil Red O staining and immunohistochemistry. Key vasorelaxant signaling proteins were quantified by q-PCR.Results: Endothelium-dependent relaxation of phenylephrine-constricted aortic rings was impaired in Apoe -/-HFD mice (53%) vs. wild-type (WT) controls (80%, P<0.0001), consistent with endothelial dysfunction. Treatment of Apoe -/-HFD mice with SKA-31, but not senicapoc, restored maximal relaxation to the WT level. Phenylephrine-evoked contraction was similar in WT and vehicle/drug treated Apoe -/-mice, as was the maximal relaxation induced by the endothelium-independent vasodilator sodium nitroprusside. mRNA expression for eNOS, KCa3.1, KCa2.3 and TRPV4 channels in the abdominal aorta was unaffected by either SKA-31 or senicapoc treatment. Fatty plaque formation, tissue collagen, α-smooth muscle actin and resident macrophages in the aortic sinus were also unaltered by either treatment vs. vehicle treated Apoe -/- HFD mice.Our data show that prolonged administration of the KCa channel activator SKA-31 improved endothelial function without modifying fatty plaque formation in the aorta of Apoe -/- mice.
Keywords: endothelial dysfunction, KCa channel activator, Aorta, Atherosclerosis, ApoE knockout mouse
Received: 13 Dec 2024; Accepted: 04 Feb 2025.
Copyright: © 2025 Vera, Mishra, Khaddaj Mallat, Hamm, Al-Marzouq, Chen, Belke, Singh, Wulff and Braun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Andrew P Braun, Physiology and Pharmacology, University of Calgary, Calgary, T2N4N1, Alberta, Canada
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.